Filing Analysis
Envoy Medical, Inc. announced the appointment of Robert Potashnick as Chief Accounting Officer and Vice President of Finance, effective August 24, 2026. Mr. Potashnick, who previously served as the company's Interim CFO on a contract basis, will continue to perform the duties of principal financial officer and principal accounting officer.
🚩 Red Flags
- The transition from an interim/contractor role to a permanent officer role can sometimes indicate ongoing leadership instability, though not explicitly stated here.
📋 Key Facts
- Robert Potashnick appointed as Chief Accounting Officer and VP of Finance on August 24, 2026.
- Mr. Potashnick will continue to serve as the company's principal financial officer and principal accounting officer.
- Compensation includes a $315,000 annual base salary and a target bonus of 15%.
- Equity award of 250,000 stock options with an exercise price of $0.746 per share.
- Mr. Potashnick previously served as Interim CFO on a contractor basis via Oasis Business Consulting, LLC.
Envoy Medical, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal notice that earnings data has been made public via a press release.
📋 Key Facts
- The company issued a press release on August 10, 2026, regarding financial results for the fiscal quarter ended June 30, 2026.
- The filing is under Item 2.02 (Results of Operations and Financial Condition).
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Envoy Medical, Inc. terminated its At The Market (ATM) Offering Agreement that had been in place since January 17, 2025. This termination ends the company's ability to issue shares directly into the market under this specific agreement.
🚩 Red Flags
- Termination of an ATM agreement can sometimes indicate a company's desire to avoid further dilution or, conversely, may suggest they no longer require immediate liquidity via this specific mechanism.
- The absence of a replacement financing plan in the filing leaves the company's future equity-based capital raising strategy unclear.
📋 Key Facts
- Termination of 'At The Market' (ATM) Offering Agreement occurred on June 24, 2026.
- The original ATM Agreement was dated January 17, 2025.
- The termination is reported under Item 1.02 of Form 8-K.
Envoy Medical, Inc. announced compensation changes for CEO Brent Lucas, including a new base salary and performance-based bonuses. The package also includes significant equity grants (1M options and 1M RSUs) tied to specific FDA approval milestones.
🚩 Red Flags
- Significant equity concentration: The CEO was granted 2 million total equity instruments (options and RSUs) which could lead to future dilution for existing shareholders.
📋 Key Facts
- CEO Brent Lucas's base salary updated to $420,000 per year.
- Targeted cash bonus of $105,000 based on strategic goals for 2026 and 2027.
- Grant of 1,000,000 stock options with an exercise price of $0.634 per share.
- Grant of 1,000,000 Restricted Stock Units (RSUs) vesting upon FDA approval of the 'Acclaim' cochlear implant.
- RSU vesting period is between June 19, 2026, and June 18, 2030.
Envoy Medical, Inc. (COCH) has received a second Nasdaq staff notification on May 19, 2026, granting an additional 180-day compliance period (until November 16, 2026) to meet the $1.00 minimum bid price requirement after failing to regain compliance within the initial 180-day period that expired on May 18, 2026. The Company has formally notified Nasdaq of its intention to cure the deficiency via a reverse stock split if necessary, signaling the stock price remains below $1.00.
🚩 Red Flags
- Stock price has been below $1.00 for an extended period — failing to recover across an entire initial 180-day compliance window.
- Company explicitly intends to pursue a reverse stock split to meet bid price requirements, a classic distress signal for micro-cap stocks.
- Warrant exercise price of $11.50 is dramatically above current market price, rendering warrants deeply out-of-the-money and effectively worthless.
- Failure to regain compliance within the first 180-day period suggests limited organic buying pressure or investor demand.
- Second compliance deadline of November 16, 2026, creates a hard deadline; failure could result in delisting proceedings.
- Reverse stock split, if executed, may reduce per-share price sensitivity and could trigger further selling pressure post-split.
📋 Key Facts
- Original Nasdaq deficiency notice received: November 19, 2025, for failure to maintain $1.00 minimum bid price (Nasdaq Listing Rule 5550(a)(2)) for 30 consecutive business days.
- Initial 180-day compliance period expired May 18, 2026, without the Company regaining compliance.
- Second staff notification received May 19, 2026, granting a second 180-day compliance period ending November 16, 2026.
- Company remains listed on Nasdaq Capital Market during the Second Compliance Period.
- Company filed written notice to Nasdaq of its intention to cure the deficiency by effecting a reverse stock split, if necessary.
- Nasdaq confirmed the Company meets all other continued listing requirements except the bid price requirement.
- Warrants (COCHW) also listed on Nasdaq, exercisable at $11.50 per share — well above current trading levels.
- Filing signed by CEO Brent Lucas on May 22, 2026.
- Company is classified as an emerging growth company.
Envoy Medical stockholders approved significant amendments to the company's equity incentive plans, authorizing an additional 7.2 million shares for issuance. The annual meeting also ratified the company's auditor and approved a prior warrant issuance to comply with Nasdaq listing rules.
🚩 Red Flags
- Significant potential shareholder dilution resulting from the authorization of 7,200,000 new shares for equity plans.
- The need for retroactive stockholder approval for a February 2026 warrant issuance suggests the previous transaction may have exceeded Nasdaq's 20% dilution threshold.
📋 Key Facts
- Authorized an additional 6,000,000 shares for the 2023 Equity Incentive Plan.
- Authorized an additional 1,200,000 shares for the 2023 Employee Stock Purchase Plan.
- Stockholders approved the issuance of warrants and underlying Class A Common Stock from a February 12, 2026 transaction to comply with Nasdaq Listing Rule 5635(d).
- Brent T. Lucas and Susan J. Kantor were elected as Class III directors with terms expiring in 2029.
- EisnerAmper, LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
Envoy Medical, Inc. reported its financial results for the fiscal quarter ended March 31, 2026. The results were furnished via a press release attached to the filing.
📋 Key Facts
- The filing reports financial results for the first quarter ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- The report includes Exhibit 99.1, which is the press release dated March 11, 2026 (noting a possible typo in the exhibit date vs filing date).
- The filing was signed by CEO Brent Lucas on May 11, 2026.
Envoy Medical appointed Charles S. McKhann to its Board of Directors and Compensation Committee, increasing the board size from six to seven. Mr. McKhann is a veteran medical device executive with a history of leading companies through successful acquisitions by major players like Boston Scientific.
📋 Key Facts
- Charles S. McKhann appointed as a Class I director on April 15, 2026, with a term expiring in 2027.
- Board size increased from six to seven members to accommodate the appointment.
- Mr. McKhann was granted 100,000 stock options at an exercise price of $0.72 per share, vesting over 36 months.
- Mr. McKhann's background includes serving as CEO of Silk Road Medical and Apollo Endosurgery, both of which were acquired by Boston Scientific Corporation.
Envoy Medical, Inc. dismissed Grant Thornton LLP and appointed EisnerAmper LLP as its new independent auditor effective March 25, 2026. The company's previous audit reports for 2024 and 2025 included going concern warnings and identified material weaknesses in internal controls.
🚩 Red Flags
- Persistent 'going concern' language in audit reports for the last two consecutive fiscal years.
- Ongoing material weaknesses in internal control over financial reporting (2024 and 2025).
- The filing was signed by an Interim Chief Financial Officer (Robert Potashnick), which may indicate management instability.
📋 Key Facts
- Grant Thornton LLP was dismissed as the independent registered public accounting firm on March 25, 2026.
- EisnerAmper LLP was appointed for the fiscal year ending December 31, 2026, following a competitive process.
- Audit reports for fiscal years ended December 31, 2024, and December 31, 2025, contained explanatory paragraphs expressing substantial doubt about the Company’s ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting were disclosed in the Company’s Annual Reports on Form 10-K for 2024 and 2025.
- No disagreements were reported between the Company and Grant Thornton on accounting principles, practices, or disclosures.
Envoy Medical, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025, via a press release on March 23, 2026.
🚩 Red Flags
- Company continues to operate with an Interim CFO (Robert Potashnick).
📋 Key Facts
- Announcement of Q4 and FY 2025 financial results.
- Press release dated March 23, 2026, furnished under Item 2.02.
- Filing signed by Interim CFO Robert Potashnick on March 27, 2026.
- The company is an emerging growth company.
Envoy Medical has regained compliance with Nasdaq's minimum market value of listed securities requirement (Rule 5550(b)(2)). While the company is no longer at immediate risk of delisting, it will be subject to a one-year discretionary panel monitor by Nasdaq.
🚩 Red Flags
- The company is subject to a one-year discretionary panel monitor, which acts as a 'probationary' period where any subsequent non-compliance could lead to accelerated delisting.
- History of listing standard deficiencies requiring a Hearing Panel intervention.
📋 Key Facts
- Received Nasdaq confirmation of compliance on February 23, 2026.
- The compliance relates to Nasdaq Listing Rule 5550(b)(2) regarding market value.
- The company was previously under review by a Nasdaq Hearing Panel as of October 23, 2025.
- A discretionary panel monitor will be in effect for one year starting February 12, 2026, pursuant to Rule 5815(d)(4)(B).
Envoy Medical, Inc. has commenced a best efforts public offering of common stock and various warrants to raise approximately $30 million in gross proceeds. The funds are intended to support operations during the FDA pivotal clinical study for its Acclaim CI device.
🚩 Red Flags
- Significant dilution: The offering involves a massive number of warrants and pre-funded warrants that could significantly dilute existing shareholders.
- Heavy reliance on milestone-based financing: Warrant expiration is tied to FDA milestones (PMA submission and approval).
- Insider participation: While insiders participated, the scale of the warrant issuance suggests high capital dependency on external investors.
- Restrictive covenants: The company agreed not to issue further convertible securities for one year following the closing.
📋 Key Facts
- Offering includes 47,946,150 shares of Class A Common Stock and 27,053,850 pre-funded warrants.
- Additional Series A-1 and A-2 Warrants totaling 120,000,000 potential shares are included in the offering structure.
- The combined purchase price for securities is $0.40 per share (or $0.3999 per pre-funded warrant).
- Gross proceeds from the offering are approximately $30 million, with a potential additional $48 million if all warrants are exercised.
- H.C. Wainwright & Co., LLC is acting as the exclusive placement agent with a 7% fee.
- The company must seek stockholder approval for the issuance of shares upon exercise of Common Warrants.
Envoy Medical, Inc. announced the issuance of stock options to its CEO and Interim CFO under the company's 2023 Equity Incentive Plan.
🚩 Red Flags
- Extremely low stock price ($0.53) relative to warrant exercise prices mentioned in header metadata ($11.50), suggesting significant dilution or distress context, though not explicitly stated as a red flag in this specific item.
- Use of an 'Interim' CFO suggests potential recent turnover or instability in the finance department.
📋 Key Facts
- CEO Brent Lucas was awarded options to purchase 200,000 shares of Class A Common Stock.
- Interim CFO Robert Potashnick was awarded options to purchase 15,000 shares of Class A Common Stock.
- The exercise price for both awards was $0.53 per share (based on the closing price on February 5, 2026).
- Vesting schedule: 25% after one year, with the remainder vesting pro rata over the following 36 months.
- Options expire 10 years from the award date.
Envoy Medical, Inc. entered into an amendment to extend the expiration date of 1,125,499 outstanding Shortfall Warrants held by Meteora Parties from December 31, 2025, to December 31, 2026.
🚩 Red Flags
- Potential dilutive pressure: The extension of over 1.1 million warrants provides a long-term mechanism for significant equity dilution.
- Related-party nature: The transaction involves specific institutional entities (Meteora Parties) linked to previous financing structures.
📋 Key Facts
- Amendment No. 4 extends the expiration date of 1,125,499 Shortfall Warrants to December 31, 2026.
- The warrants are held by Meteora Special Opportunity Fund I, LP and related entities (Meteora Parties).
- Exercise price is determined via a weekly VWAP formula with a floor of $1.50 per share.
- Warrants were issued pursuant to an Equity Prepaid Forward Transaction dated April 17, 2023.
Envoy Medical, Inc. has filed an 8-K to furnish an updated Investor Presentation under Item 7.01 (Regulation FD Disclosure). The filing does not contain material financial changes or structural corporate updates.
📋 Key Facts
- Company furnished an updated Investor Presentation as per Item 7.01.
- The presentation is intended for use in meetings with current and potential investors.
- Filing date: December 16, 2025.
Envoy Medical, Inc. held a Special Meeting of Stockholders on November 26, 2025, where shareholders approved the issuance of Class A Common Stock and redeemable warrants to comply with Nasdaq Listing Rule 5635(d). The approval facilitates a previously announced securities purchase agreement dated September 22, 2025.
🚩 Red Flags
- Requirement to seek shareholder approval under Nasdaq Rule 5635(d) often indicates the company is issuing shares/warrants that could result in significant dilution or are being issued as part of a financing deal that exceeds standard exemption limits.
📋 Key Facts
- Special Meeting held on November 26, 2025.
- Stockholders approved the issuance of warrants to purchase Class A Common Stock and the underlying shares (Issuance Proposal).
- The approval was required for compliance with Nasdaq Listing Rule 5635(d) regarding shareholder approval for certain issuances.
- Warrants are exercisable at an exercise price of $11.50 per share.
- The Issuance Proposal received 13,599,174 votes 'For'.
- The Adjournment Proposal was approved with 13,345,775 votes 'For'.
Envoy Medical, Inc. received a notice from Nasdaq informing the company that its Class A Common Stock has failed to meet the $1.00 minimum bid price requirement for continued listing.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential for mandatory reverse stock split to regain compliance
📋 Key Facts
- The deficiency is due to the stock failing the $1.00 minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)) for 30 consecutive business days prior to Nov 19, 2025.
- The company has been granted an initial compliance period of 180 calendar days, ending May 18, 2026.
- To regain compliance, the stock must close at or above $1.00 for ten consecutive business days before the Compliance Date.
- A second 180-day compliance period may be available if the company meets market value requirements and intends to cure the deficiency via a reverse stock split.
Envoy Medical, Inc. filed an 8-K to announce the release of its financial results for the third fiscal quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Third fiscal quarter ended September 30, 2025.
- Filing date: November 10, 2025.
- The company is classified as an emerging growth company.
Envoy Medical, Inc. has received a temporary exception from the Nasdaq Hearings Panel to demonstrate compliance with the $35 million market value of listed securities (MVLS) requirement through February 23, 2026.
🚩 Red Flags
- Delisting risk: The company is currently failing to meet the $35 million market value of listed securities (MVLS) requirement.
- Regulatory scrutiny: The company has already exhausted its initial 180-day cure period and required a hearing to obtain this extension.
📋 Key Facts
- The Nasdaq Hearings Panel granted an exception to demonstrate compliance with Nasdaq Listing Rule 5550(b)(2).
- The exception period extends the deadline for compliance until February 23, 2026.
- The company was initially notified of non-compliance on February 25, 2025.
- A hearing regarding the determination was held on October 2, 2025.
Envoy Medical, Inc. entered into a Securities Purchase Agreement to conduct a registered direct offering of 3,007,524 shares at $1.33 per share and a concurrent private placement of warrants totaling up to 9,022,572 shares.
🚩 Red Flags
- Significant dilution potential due to high warrant coverage (nearly 3-for-1 ratio).
- Heavy issuance of unregistered securities (Private Warrants) which will require a new S-1 registration statement.
- Placement agent receives significant compensation including additional warrants and fees on future warrant exercises.
📋 Key Facts
- Registered Offering: 3,007,524 shares of Class A common stock at $1.33 per share.
- Private Placement: Up to 9,022,572 Private Warrants with an exercise price of $1.33 per share.
- Gross Proceeds: Approximately $4.0 million from the equity sale; potential for an additional $12.0 million if warrants are fully exercised.
- Placement Agent: H.C. Wainwright & Co., LLC, receiving a 7.5% cash fee and 1.0% management fee.
- Warrant Coverage: The number of private warrants issued is roughly 3x the number of shares offered (9.02M warrants for 3.0M shares).
- Use of Proceeds: Working capital and general corporate purposes.
Envoy Medical, Inc. announced that the FDA has approved the expansion of its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to its final stage.
📋 Key Facts
- FDA approval granted to expand the pivotal clinical trial for the Acclaim® cochlear implant.
- The trial is moving into its final stage.
- The product is a fully implanted cochlear implant.
Envoy Medical, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 1,908,402 shares at $1.31 per share, alongside a concurrent private placement of warrants. The offering is intended to raise approximately $2.5 million in gross proceeds for working capital.
🚩 Red Flags
- Significant dilution risk: The issuance of over 5.7 million warrants at $1.31 represents a massive potential increase in share count relative to the current offering size.
- Warrant overhang: The company must obtain stockholder approval for the private warrants, creating regulatory/governance uncertainty.
- High cost of capital: Placement agent fees and additional management fees on warrant exercises represent significant leakage of proceeds.
📋 Key Facts
- Registered Offering: 1,908,402 shares of Class A common stock at $1.31 per share.
- Private Placement: Up to 5,725,206 Private Warrants with an exercise price of $1.31 per share.
- Expected gross proceeds from equity sale: ~$2.5 million; potential additional $7.5 million if warrants are exercised in full.
- The company must obtain stockholder approval for the warrant issuance within 90 days or hold meetings every 90 days until approved.
- H.C. Wainwright & Co., LLC is serving as the exclusive placement agent with a total cash fee of 8.5% (7.5% sales + 1.0% management) plus reimbursement for expenses.
Envoy Medical, Inc. announced the receipt of a European patent regarding an 'Implantable Cochlear System with Integrated Components and Lead Characterization.' The filing serves as a formal notification of this intellectual property development.
📋 Key Facts
- Company received a European patent titled 'Implantable Cochlear System with Integrated Components and Lead Characterization'.
- The announcement was made via press release on September 19, 2025.
- The company is an emerging growth company.
Envoy Medical entered into a Voting and Warrant Extension Agreement with Glen A. Taylor, a major shareholder owning ~47.8% of the company. The agreement includes voting commitments to ensure Nasdaq compliance through 2028 and an extension of warrant expiration dates.
🚩 Red Flags
- Significant related-party transaction involving a controlling shareholder (47.8% ownership).
- Voting agreement designed specifically to ensure Nasdaq compliance suggests potential delisting risk or structural governance issues.
- Extension of warrants for a large block of shares (3.5M) could lead to significant future dilution.
📋 Key Facts
- Glen A. Taylor (via GAT Funding, LLC and Taylor Sports Group, Inc.) owns approximately 47.8% of Class A Common Stock.
- The Taylor Parties agreed to vote their shares in favor of proposals required for Nasdaq Listing Rule compliance through December 31, 2028.
- The Company granted registration rights to the Taylor Parties for resale of shares starting March 31, 2026.
- Expiration dates for GAT Warrants (covering 3,500,000 shares) were extended from early/mid-2026/2027 to December 31, 2028.
Envoy Medical received a determination letter from Nasdaq stating it failed to regain compliance with the Minimum Market Value of Listed Securities (MVLS) requirement within the 180-day cure period. The company has filed a request for a hearing to contest the decision and avoid immediate trading suspension.
🚩 Red Flags
- Failure to meet minimum market value requirements for Nasdaq listing
- Imminent threat of trading suspension (scheduled for Sept 4, 2025) if the appeal is unsuccessful
- Historical deficiency notification dating back to February 25, 2025
📋 Key Facts
- Nasdaq determined the company did not meet the $35,000,000 MVLS Requirement during the required period.
- The 180-day cure period expired on August 26, 2025.
- Trading suspension is scheduled for September 4, 2025, unless a hearing request is filed and results in an extension.
- The company submitted a formal hearing request to the Nasdaq Hearings Panel on August 29, 2025.
- A hearing request stays the trading suspension until the Panel provides a decision.
Envoy Medical, Inc. entered into a Satisfaction Agreement with GAT Funding, LLC (controlled by the company's largest stockholder, Glen Taylor) to extinguish over $32 million in debt for a single payment of $100,000. Simultaneously, Glen Taylor resigned from the Board of Directors.
🚩 Red Flags
- Related-party transaction involving the largest stockholder and significant debt forgiveness/settlement.
- Extreme disparity between debt extinguished ($32M+) and payment made ($100k), suggesting highly favorable terms for the insider.
- Simultaneous departure of the largest stockholder from the Board of Directors following a massive debt settlement.
📋 Key Facts
- On August 25, 2025, the Company paid GAT Funding, LLC $100,000 to fully satisfy all obligations under three promissory notes issued on Feb 27, 2024, Aug 27, 2024, and March 6, 2025.
- The total amount of principal and accrued interest extinguished was $32,011,552.
- GAT Funding, LLC is controlled by Glen Taylor, the Company's largest stockholder.
- The Satisfaction Agreement was approved by the Audit Committee, which consists of all independent directors; Mr. Taylor did not serve on this committee.
- Glen Taylor resigned from the Board of Directors effective August 25, 2025, citing a desire to focus on other business interests.
Envoy Medical, Inc. filed an 8-K to announce its financial results for the second fiscal quarter ended June 30, 2025. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Second fiscal quarter ended June 30, 2025.
- Filing date: July 31, 2025.
- The company is an 'emerging growth company' as defined by the SEC.
- Financial results were released via press release (Exhibit 99.1).
Envoy Medical, Inc. entered into an amendment to its outstanding Shortfall Warrants with the Meteora Parties. The amendment changes the exercise price of 3,209,511 warrants to a weekly VWAP formula with a $1.50 per share floor.
🚩 Red Flags
- Significant dilution potential: Over 3.2 million warrants remain outstanding which can be exercised at a potentially low price (floor of $1.50).
- Variable exercise price: The VWAP-based pricing mechanism often indicates a need for immediate liquidity or is used to compensate lenders/investors for risk.
📋 Key Facts
- Amendment No. 3 to Common Stock Purchase Warrant executed on July 28, 2025.
- Affects 3,209,511 Shortfall Warrants previously issued to Meteora Parties.
- New exercise price is determined by a weekly volume weighted average price (VWAP) formula.
- The amendment includes a minimum exercise price floor of $1.50 per share.
- Warrants are linked to an Equity Prepaid Forward Transaction dated April 17, 2023.
Envoy Medical, Inc. has drawn the remaining $5,000,000 of a promissory note from GAT Funding, LLC, an entity controlled by board member and controlling stockholder Glen Taylor. As part of this transaction, the company issued 750,000 warrants to GAT at an exercise price of $1.48 per share.
🚩 Red Flags
- Related-party transaction involving the controlling stockholder and board member.
- Issuance of 750,000 warrants as a 'commitment fee' for drawing down debt may be viewed as highly dilutive to existing shareholders.
- Dependency on financing from an insider/controlling stakeholder.
📋 Key Facts
- Company drew remaining $5,000,000 principal from a promissory note dated March 6, 2025.
- The lender, GAT Funding, LLC, is controlled by Glen Taylor (Board Member and controlling stockholder).
- Issued 750,000 Class A Common Stock warrants to GAT as a commitment fee.
- Warrant exercise price: $1.48 per share (based on the closing price on the date of the draw).
- Warrants have a two-year exercise period.
Envoy Medical, Inc. announced the appointment of Robert Potashnick as Interim Chief Financial Officer, effective June 23, 2025. Mr. Potashnick will serve on a fractional consultant basis through his entity, Oasis Business Consulting LLC.
🚩 Red Flags
- Appointment of an 'Interim' CFO often suggests sudden departure of the previous officer or internal instability in the finance department.
- The use of a fractional consultant (Oasis Business Consulting LLC) rather than a full-time executive can indicate a transitional period or budget constraints.
📋 Key Facts
- Robert Potashnick appointed as Interim CFO, Principal Financial Officer, and Principal Accounting Officer.
- Appointment effective date: June 23, 2025.
- Engagement is on a fractional consultant basis via Oasis Business Consulting LLC.
- Mr. Potashnick previously served at Flutterbee Education Group and FOXO Technologies Inc.
Envoy Medical, Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025. The meeting resulted in the election of two directors, ratification of Grant Thornton LLP as independent auditors, and approval of an amendment to the 2023 Equity Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 28, 2025.
- Stockholders approved an amendment to the 2023 Equity Incentive Plan to remove a restriction on 1,500,000 shares previously tied to a regulatory milestone.
- Janis Smith-Gomez and Chuck Brynelsen were elected to the Board of Directors.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Non-binding advisory vote approved named executive officer compensation.
Envoy Medical, Inc. announced the departure of its Chief Financial Officer, David R. Wells, effective May 16, 2025. The separation was without cause, and CEO Brent T. Lucas will serve as interim Principal Financial Officer.
🚩 Red Flags
- Sudden departure of a CFO in a micro-cap company can sometimes signal internal friction or disagreements over financial reporting, though 'without cause' is intended to mitigate this perception.
- CEO taking on interim PFO duties increases the management burden on the CEO during a transition period.
📋 Key Facts
- David R. Wells ceased serving as CFO on May 16, 2025.
- The departure is noted as being 'without cause'.
- Mr. Wells is entitled to separation compensation per his August 15, 2023 Employment Agreement.
- CEO Brent T. Lucas will assume the role of interim Principal Financial Officer.
Envoy Medical, Inc. filed an 8-K to announce its financial results for the first fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings press release.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 31, 2025.
- Filing date: May 1, 2025.
- The company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
- Includes Exhibit 99.1 (Press Release dated May 1, 2025).
Envoy Medical, Inc. has announced the date and location for its upcoming Annual Meeting of Stockholders scheduled for May 28, 2025. The filing also outlines specific deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: Wednesday, May 28, 2025, at 3:00 p.m. CT.
- Meeting Location: Fairfield Inn & Suites, Vadnais Heights, Minnesota.
- Record Date for Voting: Holders of record as of the close of business on April 8, 2025.
- Deadline for Director Nominations/Proposals: Written notice must be received by the corporate secretary by April 20, 2025.
- The company noted a change in meeting timing from October to May.
Envoy Medical, Inc. filed an 8-K to announce its financial results for the fourth fiscal quarter and full fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Fourth fiscal quarter and fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results
- Company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
Envoy Medical, Inc. entered into a $10 million promissory note agreement with GAT Funding, LLC, an entity controlled by a board member and controlling stockholder, Glen Taylor. The deal includes significant warrant issuances as commitment fees.
🚩 Red Flags
- Related-party transaction involving the controlling stockholder and a board member.
- Significant dilution potential via warrant issuance (750,000 shares for initial funding).
- Highly favorable terms for the insider (low exercise price of $1.35 relative to typical market dynamics, though specific market price context is needed).
📋 Key Facts
- Principal amount of the Note: Up to $10,000,000.
- Counterparty: GAT Funding, LLC (controlled by board member/controlling stockholder Glen Taylor).
- Initial funding at closing: $5,000,000 principal.
- Interest rate: 8.0% per annum, compounding for the first two years; paid quarterly thereafter.
- Maturity date: March 6, 2030 (five-year term).
- Warrants issued to GAT: 750,000 Class A Common Stock warrants at an exercise price of $1.35 per share for the initial $5,000,000 funding.
- Commitment fee structure: 375,000 warrants for every $2,500,000 in principal funded.
Envoy Medical, Inc. received a deficiency notification from Nasdaq because its listed securities failed to meet the $35 million minimum market value requirement for 31 consecutive business days between January 7 and February 24, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum market value requirement (Rule 5550(b)(2))
- Risk of delisting if compliance is not met by August 25, 2025
📋 Key Facts
- Received deficiency notice on February 25, 2025.
- Violation of Nasdaq Listing Rule 5550(b)(2) regarding minimum market value ($35M requirement).
- The company has a 180-day compliance period to regain status, expiring August 25, 2025.
- To regain compliance, the market value must exceed $35,000,000 for ten consecutive business days.
Envoy Medical, Inc. entered into an At The Market (ATM) offering agreement with Roth Capital Partners, LLC to facilitate the sale of up to $15 million in Class A common stock.
🚩 Red Flags
- Potential dilution for existing shareholders via the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can signal a need for liquidity.
📋 Key Facts
- Entered into an At The Market Offering Agreement on January 17, 2025.
- Sales Agent: Roth Capital Partners, LLC.
- Aggregate offering amount: Up to $15,000,000 in Class A common stock.
- Commission: Up to 3.0% of gross proceeds plus reimbursement for legal fees up to $50,000.
- The offering will be conducted under an existing S-3 registration statement declared effective on October 21, 2024.
Envoy Medical, Inc. has entered into a second amendment to its Common Stock Purchase Warrant with the Meteora FPA Parties. This amendment extends the expiration date of 3,874,394 'Shortfall Warrants' by an additional 12 months, moving the deadline from December 31, 2024, to December 31, 2025.
🚩 Red Flags
- Repeated extensions: This is the second amendment to extend warrant expiration, suggesting the company has been unable to satisfy previous terms or resolve the underlying shortfall within the original timeframe.
- Potential dilution: The warrants represent a significant number of shares (3.87M) that could be issued at $10.46 per share.
📋 Key Facts
- Amendment No. 2 extends the expiration of Shortfall Warrants from Dec 31, 2024, to Dec 31, 2025.
- The warrants allow for the purchase of up to 3,874,394 shares of Class A common stock.
- The exercise price for these Shortfall Warrants is $10.46 per share.
- The transaction involves Meteora Special Opportunity Fund I, LP and related entities (Meteora FPA Parties).
- The warrants were originally issued as part of an OTC Equity Prepaid Forward Transaction.
Envoy Medical, Inc. entered into a Conversion and Waiver Agreement with its former SPAC sponsor, Anzu SPAC GP I LLC, to resolve outstanding dividend obligations and share restrictions. The agreement includes a significant temporary reduction in the preferred stock conversion price from $11.50 to $3.63.
🚩 Red Flags
- Significant dilution risk: The temporary reduction in conversion price (from $11.50 to $3.63) allows for a massive increase in common shares issued upon conversion.
- Related-party transaction: The agreement is with the former SPAC sponsor (Anzu), which had significant unvested/restricted holdings.
- Potential 'dump' of shares: The waiver of restrictions on 1,000,000 shares makes them immediately tradable, potentially increasing selling pressure.
📋 Key Facts
- Effective date of transactions: December 20, 2024.
- Anzu waived $3,733,333 in accrued dividends on Preferred Stock.
- The Company waived vesting/restriction requirements for 1,000,000 shares held by Anzu, making them freely tradable.
- A temporary reduction in the conversion price of Preferred Stock from $11.50 to $3.63 is in effect from Dec 20, 2024, through Jan 20, 2025.
- Anzu converted 373,333 shares of Preferred Stock into 1,028,986 shares of Common Stock at the reduced conversion price.
Envoy Medical, Inc. has drawn an additional $5 million from a promissory note issued to GAT Funding, LLC, bringing the total principal to $10 million. The lender is controlled by Glen Taylor, a board member and controlling stockholder of the company.
🚩 Red Flags
- Related-party transaction: The debt and warrant issuance are to an entity controlled by a board member/controlling stockholder.
- Potential dilution: Issuance of 500,000 warrants to an insider as a commitment fee for debt.
📋 Key Facts
- Company drew $5,000,000 under an existing promissory note on December 11, 2024.
- Aggregate principal amount of the Note is now $10,000,000.
- The lender, GAT Funding, LLC, is controlled by Glen Taylor (Board Member and controlling stockholder).
- Company issued a warrant to GAT for 500,000 shares of Class A Common Stock as a commitment fee.
- Warrant exercise price is $2.20 per share; termination date is December 11, 2026.
Envoy Medical, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on November 14, 2024. The meeting included the election of two directors and the ratification of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Held 2024 Annual Meeting of Stockholders on November 14, 2024.
- Elected Michael Crowe and Mona Patel to the Board of Directors.
- Ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Stockholders approved (non-binding) named executive officer compensation.
- Stockholders recommended a one-year frequency for advisory votes on executive compensation; Board adopted this recommendation.
Envoy Medical, Inc. filed an 8-K to announce its third fiscal quarter financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Third fiscal quarter ended September 30, 2024
- The filing includes a press release regarding financial results (Exhibit 99.1)
- Company is an emerging growth company
Envoy Medical, Inc. announced the date and location for its upcoming Annual Meeting of Stockholders scheduled for November 14, 2024. The filing also outlines specific deadlines for stockholder proposals and director nominations.
🚩 Red Flags
- The company did not hold an annual meeting of stockholders in 2023, which may indicate previous administrative or procedural delays.
📋 Key Facts
- Annual Meeting Date: Thursday, November 14, 2024, at 3:00 p.m. CT.
- Meeting Location: Delta Hotels Minneapolis Northeast, 1330 Industrial Blvd NE, Minneapolis, Minnesota.
- Record Date for Voting: Holders of record as of the close of business on September 16, 2024.
- Deadline for Director Nominations/Proposals (Rule 14a-8): Written notice must be received by the corporate secretary by September 16, 2024.
- Company did not hold an annual meeting in 2023.
Envoy Medical, Inc. entered into a $10 million promissory note agreement with GAT Funding, LLC, an entity controlled by board member and controlling stockholder Glen Taylor. The company has already drawn $5 million of the principal at closing.
🚩 Red Flags
- Related-party transaction involving a controlling stockholder and board member.
- Potential for significant dilution via the issuance of 500,000+ warrants to an insider entity.
- Compounding interest structure on the first two years increases the total debt burden.
📋 Key Facts
- Total Note amount: Up to $10,000,000 in $2,500,000 tranches.
- Counterparty: GAT Funding, LLC (controlled by Glen Taylor, a board member and controlling stockholder).
- Initial draw: $5,000,000 at initial closing.
- Interest rate: 8.0% per annum, compounding for the first two years before quarterly payments begin.
- Maturity date: August 27, 2029 (5-year term).
- Warrants issued: 500,000 Class A Common Stock warrants at an exercise price of $2.97 per share for the initial $5 million draw.
- Commitment fee: 250,000 warrants per $2,500,000 in principal funded.
Envoy Medical, Inc. filed an 8-K to announce its financial results for the second fiscal quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings press release issued on August 12, 2024.
📋 Key Facts
- Reporting period: Second fiscal quarter ended June 30, 2024.
- Filing date: August 12, 2024.
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Envoy Medical, Inc. issued an 8-K to announce its support for the bipartisan Senate bill 'Hearing Device Coverage Clarification Act (S.4829)'. The legislation aims to reclassify implanted active middle ear hearing devices as prosthetics to avoid Medicare coverage exclusions.
📋 Key Facts
- The company is supporting S.4829, a bipartisan Senate bill.
- The bill seeks to clarify that implanted active middle ear hearing devices should be classified as prosthetics.
- The goal of the legislation is to prevent these devices from being subject to current Medicare hearing aid coverage exclusions.
Envoy Medical, Inc. entered into an amendment to its Forward Purchase Agreement with Meteora FPA Parties on July 29, 2024. The amendment lowers the exercise price floor for a portion of previously issued Shortfall Warrants.
🚩 Red Flags
- Significant reduction in exercise price floors (from $4.00 down to $2.00 and $3.00) suggests potential dilution pressure or a need to incentivize warrant exercise.
- The use of 'Shortfall Warrants' and 'Forward Purchase Agreements' is often associated with complex financing structures used by micro-cap companies to manage liquidity.
📋 Key Facts
- Amendment dated July 29, 2024, to the Forward Purchase Agreement originally entered into April 17, 2023.
- The amendment modifies the Exercise Price Floor for certain Shortfall Warrants issued to Meteora FPA Parties.
- New floor of $2.00 applies to 1,000,000 Shortfall Warrants.
- New floor of $3.00 applies to an additional 1,000,000 Shortfall Warrants.
- The remaining Shortfall Warrants retain the original $4.00 Exercise Price Floor.
Envoy Medical, Inc. drew $2.5 million from a promissory note issued to GAT Funding, LLC, an entity controlled by board member and controlling stockholder Glen Taylor. This draw increases the total principal owed to $10 million and includes the issuance of 250,000 warrants as a commitment fee.
🚩 Red Flags
- Related-party transaction: The lender (GAT Funding, LLC) is controlled by a board member and controlling stockholder (Glen Taylor).
- Increased debt load: The company has reached the maximum principal amount of $10 million on this note.
- Potential dilution: Issuance of 250,000 warrants as a commitment fee for a relatively small draw ($2.5M).
📋 Key Facts
- Company drew $2,500,000 under an existing promissory note on July 22, 2024.
- The total aggregate principal amount owed to GAT Funding, LLC is now $10,000,000.
- GAT Funding, LLC is controlled by Glen Taylor, a board member and controlling stockholder of Envoy Medical.
- As a commitment fee for the draw, the Company issued 250,000 warrants to GAT Funding, LLC.
- The warrant exercise price is $2.25 per share (based on the closing price on the date of the draw).
- Warrants expire on February 27, 2026.
Envoy Medical, Inc. filed an 8-K to furnish an updated Investor Presentation intended for use in meetings with current and potential investors.
📋 Key Facts
- The company is furnishing an updated Investor Presentation (Exhibit 99.1).
- Management intends to use the presentation in upcoming investor meetings.
- The filing includes a disclaimer that the information is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Envoy Medical, Inc. entered into an amendment to its Common Stock Purchase Warrant with Meteora FPA Parties. The amendment extends the expiration date of 3,874,394 'Shortfall Warrants' by six months.
🚩 Red Flags
- Extension of warrant expiration suggests the underlying debt/transaction has not been settled or converted as originally intended, potentially delaying capital infusion or dilution events.
- The presence of 'Shortfall Warrants' often indicates a mechanism to bridge gaps in previous financing rounds, which can lead to significant future dilution.
📋 Key Facts
- Amendment No. 1 to the Common Stock Purchase Warrant was executed on June 24, 2024.
- The amendment extends the expiration date of the Shortfall Warrants from June 30, 2024, to December 31, 2024.
- The warrants allow for the purchase of up to 3,874,394 shares of Class A common stock at an exercise price of $10.46 per share.
- The transaction is part of a previously disclosed OTC Equity Prepaid Forward Transaction with Meteora FPA Parties.
Envoy Medical, Inc. announced the immediate resignation of Dr. Whitney Haring-Smith from its Board of Directors and the subsequent appointment of Michael Crowe to fill the vacancy.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Dr. Whitney Haring-Smith resigned effective June 6, 2024; no disagreement with the company was reported.
- Michael Crowe appointed to the Board on June 7, 2024.
- Mr. Crowe brings extensive medical device industry experience, including roles at Bioventus LLC and Abbott Vascular.
- Compensation for Mr. Crowe includes $40,000 annual cash compensation and a stock option award for 25,000 shares of Class A Common Stock vesting over four years.
Envoy Medical, Inc. drew $2.5 million from a promissory note held by GAT Funding, LLC, an entity controlled by board member and controlling stockholder Glen Taylor. This draw increases the total debt to $7.5 million of a $10 million maximum.
🚩 Red Flags
- Related-party transaction involving a controlling stockholder and board member.
- Issuance of warrants to an insider as a commitment fee for debt funding.
- Increasing reliance on high-cost/insider-controlled debt (aggregate $7.5M owed).
📋 Key Facts
- Company drew $2,500,000 from an existing promissory note on May 23, 2024.
- The lender is GAT Funding, LLC, controlled by Glen Taylor (Board Member and controlling stockholder).
- Aggregate principal amount owed under the Note is now $7,500,000 out of a $10,000,000 maximum.
- Company issued 250,000 warrants to GAT Funding as a commitment fee for the draw.
- Warrant exercise price: $3.04 per share (based on closing price at time of draw).
- Warrant termination date: February 27, 2026.
Envoy Medical, Inc. filed an 8-K to announce its financial results for the first fiscal quarter ended March 31, 2024. The filing serves as a formal announcement of the earnings release issued on May 15, 2024.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 31, 2024.
- Filing date: May 15, 2024.
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Company is an emerging growth company.
Envoy Medical entered into a $10 million promissory note agreement with GAT Funding, LLC, an entity controlled by board member and controlling stockholder Glen Taylor. The deal includes significant warrant issuances to the insider as a commitment fee.
🚩 Red Flags
- Related-party transaction involving a controlling stockholder and board member.
- Issuance of warrants to an insider as a 'commitment fee' is highly dilutive and non-standard for arm's length transactions.
- The note structure involves compounding interest that is added to the principal balance, increasing total debt obligation.
📋 Key Facts
- Issued a promissory note effective February 27, 2024, for up to $10,000,000 with GAT Funding, LLC.
- GAT Funding, LLC is controlled by Glen Taylor, a board member and controlling stockholder of Envoy Medical.
- The Note has a five-year term maturing on February 27, 2029.
- Interest rate is 8.0% per annum; interest accrues for the first two years before being paid quarterly in arrears.
- Initial funding at closing was $5,000,000 of the principal amount.
- Company issued warrants to GAT to purchase 500,000 shares of Class A Common Stock at an exercise price of $1.24 per share as a commitment fee for the initial funding.